Hepatitis C in Pregnancy

Dibba, Pratima; Cholankeril, Rosann; Li, Andrew A.; Patel, Meera; Fayek, Mariam; Dibble, Christy; Okpara, Nnenna; Hines, Autumn

doi:10.3390/diseases6020031

Cited by 38 publications

(50 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 14 patients enrolled in the pharmacokinetic lead-in phase had a median age of 5 years (range, 3-5), 12 were white (86%), and 9 were female (64%), with a median weight of 20 kg (range, 12-28). Median BMI was 16 kg/m 2 (range, [14][15][16][17][18][19] with a corresponding median BMI for age percentile of 73% (range, 2-98). Of the 14 patients enrolled, 13 were included in the intensive pharmacokinetic analysis.…”

Section: Pharmacokineticsmentioning

confidence: 99%

“…(10)(11)(12)(13) Following perinatal transmission of HCV, in the absence of treatment, the rate of spontaneous clearance of the infection is reportedly between 11% and 25% and usually occurs within the first 4 years of life. (3,14) In children who become chronically infected, the course of infection is usually slower than in adults; however, liver disease can progress during early life, (15) and cases of cirrhosis, (16)(17)(18) hepatocellular carcinoma (HCC), (19,20) and end-stage liver disease (ESLD) requiring liver transplantation (LT) in childhood (21,22) have been reported.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Ledipasvir‐Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C

et al. 2019

View full text Add to dashboard Cite

For children under 12 years of age who have chronic hepatitis C virus (HCV) infection, there are currently no approved treatments with direct‐acting antiviral agents. We therefore evaluated the safety and efficacy of ledipasvir‐sofosbuvir in HCV‐infected children aged 3 to <6 years. In an open‐label study, patients 3 to <6 years old chronically infected with HCV genotype 1 (n = 33) or 4 (n = 1) received weight‐based doses of combined ledipasvir‐sofosbuvir as granules (33.75 mg/150 mg for weights <17 kg or 45 mg/200 mg for weights ≥17 kg) for 12 weeks. The primary endpoint was sustained virological response 12 weeks after treatment (SVR12). For the first 14 patients, intensive pharmacokinetic sampling was done on day 10 of treatment. All patients had been infected through perinatal transmission and were treatment naïve. No patients had known cirrhosis. Ten patients (29%) weighed <17 kg. SVR12 was achieved in 97% of patients (33 of 34); the patient who did not achieve SVR12 was 3 years old and discontinued treatment after 5 days because of an adverse event “abnormal drug taste.” The most common adverse events were vomiting (24% of patients), cough (21%), and pyrexia (21%). No patients experienced a serious adverse event. Intensive pharmacokinetic analysis of 13 patients for whom data were evaluable confirmed that the doses selected were appropriate. Conclusion: Ledipasvir‐sofosbuvir was well tolerated and highly effective in children 3 to <6 years old with chronic HCV infection.

show abstract

Section: Pharmacokineticsmentioning

confidence: 99%

mentioning

confidence: 99%

Ledipasvir‐Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Pregnancy has little to no substantial effect on the progression of active HCV infection. Maternal serum aminotransferase levels tend to fall during pregnancy, possibly reflecting the less immune‐reactive state of pregnancy . These changes may be related to the influence of immunosuppressive cytokines synthesized during pregnancy.…”

Section: Influence Of Hcv On Maternal and Fetal Outcomesmentioning

confidence: 84%

“…Maternal serum aminotransferase levels tend to fall during pregnancy, possibly reflecting the less immune-reactive state of pregnancy. (16) These changes may be related to the influence of immunosuppressive cytokines synthesized during pregnancy. Minor increases in HCV RNA can occur, especially during the second and third trimesters.…”

Section: Influence Of Hcv On Maternal and Fetal Outcomesmentioning

confidence: 99%

Hepatitis C in Pregnancy: A Unique Opportunity to Improve the Hepatitis C Cascade of Care

Kushner

Terrault

2018

Hepatol Commun

View full text Add to dashboard Cite

show abstract

“…9 Though pregnancy does not influence progression of active infection but most of the pregnant women are found to have chronic hepatitis C during pregnancy. 7,15 The usual treatment for this infection is the combined administration of ribavirin and pegylated interferon alpha. Nevertheless, this combination cannot be used in a pregnant lady because of teratogenic and IUGR (intrauterine growth retardation) effects of these drugs.…”

mentioning

confidence: 99%

Hepatitis C in pregnancy: an observational study highlighting its association with maternal parameters

Bushra¹,

Ghori²,

Ahmed³

et al. 2019

Int J Res Med Sci

View full text Add to dashboard Cite

Background: Pregnancy is a very crucial time in a woman’s life. In this period of time, not only multiple physiological alterations effect the usual health status but also makes women more vulnerable to contract infection and face negative sequalae. Hepatitis C, a blood borne viral infection serve the similar fate when encountered by pregnant ladies. This study is based on exploring the prevalence of the Hepatitis C virus seropositivity among pregnant population. Moreover, we also evaluated the major risk factors leading to the infection in these mothers. Besides this, infected mothers were studied for their pregnancy outcomes.Methods: In this study 114 pregnant females were observed for this cross-sectional study. It was conducted in Gynecology Unit- 1, Liaquat University Hospital Hyderabad, for the period of January 2017 to July 2017. Chi square test was applied for statistical analysis on SPSS version 16. The criteria for enrollment in the study was set to be a pregnant lady belonging to age group 20-35 years; having singleton pregnancy; was a booked case at the hospital with compliant to antenatal follow ups; admitted to the labor room for delivery. All the non-pregnant ladies, whom had co morbid conditions such as hypertension or diabetes or had infected with hepatitis B or D were excluded from the study. Furthermore, pregnant ladies with multiple gestion or those who were either diagnosed of hepatitis C prior to conceive or had a previous history of hepatitis C were also excluded.Results: Present study revealed that out of 114, 10(8.8%) pregnant ladies were found seropositive for Hepatitis C virus. Prior history for transfusion of blood was the Foremost risk factor discovered, with 60.5% women reported this. History of surgery was the 2nd commonest factor and 43.9% had this in their medical records. On the other hand, only 8.8% women gave the history for previous evacuation. While observing pregnancy outcomes, we found 48.2% neonates had low birth weight, 41.2% were born preterm and 21.1% had low APGAR score.Conclusions: In a nutshell hepatitis c is prevalent in the pregnant population of this region and showing its effects in the form of compromised pregnancies. History of blood transfusion and previous surgery were found to be chief risk factors in the study.

show abstract

Hepatitis C in Pregnancy

Cited by 38 publications

References 66 publications

Ledipasvir‐Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C

Ledipasvir‐Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C

Hepatitis C in Pregnancy: A Unique Opportunity to Improve the Hepatitis C Cascade of Care

Hepatitis C in pregnancy: an observational study highlighting its association with maternal parameters

Contact Info

Product

Resources

About